A biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer.


Updates from The Motley Fool

Latest updates on Keryx Biopharmaceuticals from Fool.com.


Stock Performance

KERX vs. S&P 500 | 2 Year Performance
View Interactive KERX Charts
Sponsored by

Key Data Points

Primary metrics and data points about Keryx Biopharmaceuticals.
Current Price: $7.42
Prev Close: $7.51
Open: $7.48
Bid: $7.22
Ask: $7.45
Day's Range: $7.34 - $7.51
52wk Range: $2.80 - $9.59
Volume: 821,697
Avg Vol 1,288,290
Market Cap: $780.53M
P/E (ttm): -5.78
EPS (ttm): -$1.30
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Keryx Biopharmaceuticals.
CAPS Rating 2 out of 5
 
396 Outperform
68 Underperform
CAPS All Stars
 
45 Outperform
22 Underperform

How do you think Keryx Biopharmaceuticals will perform against the market?



You pick for Keryx Biopharmaceuticals is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Ron Bentsur, CEO

0% Approve

Based on 0 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Keryx Biopharmaceuticals.

A biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers